Clicky

Regeneron Pharmaceuticals, Inc.(REGN) News

Date Title
Feb 24 Latest DB-OTO Results Demonstrate Clinically Meaningful Hearing Improvements in Nearly All Children with Profound Genetic Hearing Loss in CHORD Trial
Feb 24 Regeneron Pharmaceuticals (REGN): Among the Best Growth Stocks to Invest In According to Analysts
Feb 24 The Zacks Analyst Blog Highlights Merck, Sanofi, Regeneron and Ionis
Feb 21 2 Healthcare Stocks with Big Upside and 1 to Skip
Feb 18 FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea
Feb 18 SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag
Feb 18 FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid
Feb 18 Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)
Feb 14 Alnylam Q4 Earnings Beat Estimates, Product Revenues Rise Y/Y
Feb 13 Regeneron Pharmaceuticals' (NASDAQ:REGN) earnings growth rate lags the 11% CAGR delivered to shareholders
Feb 11 Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma
Feb 10 Regeneron’s macular oedema therapy shows promise in Phase III trial
Feb 10 Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move
Jan 24 Is Regeneron Pharmaceuticals, Inc. (REGN) the Best Falling Stock to Invest in Right Now?
Jan 23 America's Top 40 High School Scientists to Compete for $1.8 Million in Awards at Prestigious Regeneron Science Talent Search
Jan 21 REGENERON EXPANDS PRESENCE IN CANADA BY OPENING ITS FIRST HEADQUARTERS TO BETTER SERVE NEEDS OF CANADIANS WITH SERIOUS DISEASES
Jan 19 Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘This Company Has Never Lost Its Ability To Develop New Medicines’
Jan 7 Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025
Jan 6 Ultragenyx’s Evkeeza secures EU approval for young children with rare cholesterol disorder
Jan 2 1 Beaten-Down Stock That Could Soar by 50% in 2025, According to Wall Street